Display options
Cite
Carta MG, Pala AN, Finco G, et al. Depression and cerebrovascular disease: could vortioxetine represent a valid treatment option?. Clin Pract Epidemiol Ment Health. 2015;11:144-9doi: 10.2174/1745017901511010144.
Carta, M. G., Pala, A. N., Finco, G., Musu, M., & Moro, M. F. (2015). Depression and cerebrovascular disease: could vortioxetine represent a valid treatment option?. Clinical practice and epidemiology in mental health : CP & EMH, 11144-9. https://doi.org/10.2174/1745017901511010144
Carta, Mauro Giovanni, et al. "Depression and cerebrovascular disease: could vortioxetine represent a valid treatment option?." Clinical practice and epidemiology in mental health : CP & EMH vol. 11 (2015): 144-9. doi: https://doi.org/10.2174/1745017901511010144
Carta MG, Pala AN, Finco G, Musu M, Moro MF. Depression and cerebrovascular disease: could vortioxetine represent a valid treatment option?. Clin Pract Epidemiol Ment Health. 2015 Feb 27;11:144-9. doi: 10.2174/1745017901511010144. eCollection 2015. PMID: 25893002; PMCID: PMC4397833.
Copy Download .nbib Format: NLM
Share it on

Clin Pract Epidemiol Ment Health. 2015 Feb 27;11:144-9. doi: 10.2174/1745017901511010144. eCollection 2015.

Depression and cerebrovascular disease: could vortioxetine represent a valid treatment option?.

Clinical practice and epidemiology in mental health : CP & EMH

Mauro Giovanni Carta, Andrea Norcini Pala, Gabriele Finco, Mario Musu, Maria Francesca Moro

Affiliations

  1. Department of Public Health and Clinical and Molecular Medicine, University of Cagliari, Cagliari, Italy.
  2. New York State Psychiatric Institute (NYSPI), New York, NY, USA.
  3. Department of Medical Science, University of Caglairi, Italy.

PMID: 25893002 PMCID: PMC4397833 DOI: 10.2174/1745017901511010144

Abstract

INTRODUCTION: Depression and cerebrovascular atherosclerosis often occur in comorbidity showing neuropsychological impairment and poor response to antidepressant treatment. Objective is to evaluate if new antidepressant vortioxetine may be a potential treatment option. Mechanism of Action : Vortioxetine has 5-HT3, 5-HT7 and 5-HT1D antagonists, 5-HT1B partial agonist and a 5-HT1A agonist and serotonin transporter inhibitor property. Efficacy and safety in Major Depressive Disorders and in cognitive impairment : The majority of trials (one of them in older people) showed efficacy for vortioxetine against placebo and no differences against other active treatments. The Adverse Effects ranged from 15.8% more to 10.8% less than placebo. In the elderly, only nausea was found higher than placebo. Effects on arterial blood pressure and cardiac parameters including the ECG-QT segment were similar to placebo. Elderly depressive patients on vortioxetine showed improvement versus placebo and other active comparators in Auditory Verbal Learning Test and Digit Symbol Substitution Test scores. The inclusion criteria admitted cases with middle cerebrovascular disease. Conclusion : The mechanism of action, the efficacy on depression and safety profile and early data on cognitive impairment make Vortioxetine a strong candidate for use in depression associated with cerebrovascular disease. This information must be supported by future randomized controlled trials.

Keywords: Cerebrovascular disease; major depressive disorders; vascular depression; vortioxetine

References

  1. Pharmacol Ther. 2013 Jan;137(1):119-31 - PubMed
  2. Eur Neuropsychopharmacol. 2014 Jan;24(1):160-71 - PubMed
  3. Am J Geriatr Psychiatry. 2011 Feb;19(2):99-103 - PubMed
  4. Neurosci Biobehav Rev. 2014 Nov;47:369-83 - PubMed
  5. Int Clin Psychopharmacol. 2014 May;29(3):138-49 - PubMed
  6. J Psychopharmacol. 2012 Nov;26(11):1408-16 - PubMed
  7. Circulation. 2010 Feb 23;121(7):948-54 - PubMed
  8. Am J Alzheimers Dis Other Demen. 2011 May;26(3):169-83 - PubMed
  9. J Psychopharmacol. 2014 Oct;28(10):891-902 - PubMed
  10. Circulation. 2011 Jul 26;124(4):e54-130 - PubMed
  11. Am J Cardiol. 2011 Apr 1;107(7):972-9 - PubMed
  12. Stroke. 2014 Aug;45(8):2366-71 - PubMed
  13. Behav Brain Funct. 2012 Dec 19;8:61 - PubMed
  14. Nihon Ronen Igakkai Zasshi. 2009 May;46(3):250-8 - PubMed
  15. Eur Neuropsychopharmacol. 2013 Feb;23(2):133-45 - PubMed
  16. Trends Neurosci. 1996 Sep;19(9):378-83 - PubMed
  17. Neuropsychiatr Dis Treat. 2014 Jul 15;10:1297-307 - PubMed
  18. Curr Med Chem. 2015;22(3):343-51 - PubMed
  19. Biol Psychiatry. 2005 Aug 15;58(4):297-306 - PubMed
  20. Am J Psychiatry. 2010 Nov;167(11):1305-20 - PubMed
  21. J Neurosci. 2008 Nov 12;28(46):11760-7 - PubMed
  22. J Clin Psychiatry. 2012 Jul;73(7):953-9 - PubMed
  23. Int J Neuropsychopharmacol. 2013 Mar;16(2):313-21 - PubMed
  24. Heart Lung. 2009 Mar-Apr;38(2):151-62 - PubMed
  25. Hippocampus. 2012 Apr;22(4):762-71 - PubMed
  26. Neuropharmacology. 2013 Jul;70:211-7 - PubMed
  27. Int J Neuropsychopharmacol. 2012 Jun;15(5):589-600 - PubMed
  28. Drug Metab Dispos. 2012 Jul;40(7):1357-65 - PubMed
  29. Eur Neuropsychopharmacol. 2012 Jul;22(7):482-91 - PubMed
  30. Am J Geriatr Psychiatry. 2002 Jan-Feb;10(1):98-106 - PubMed
  31. J Neurol Neurosurg Psychiatry. 2004 Sep;75(9):1304-8 - PubMed
  32. Gen Hosp Psychiatry. 2007 Sep-Oct;29(5):409-16 - PubMed
  33. Curr Treat Options Psychiatry. 2014 Mar 1;1(1):1-14 - PubMed
  34. J Pharmacol Exp Ther. 2012 Mar;340(3):666-75 - PubMed
  35. Biol Psychiatry. 2004 Feb 15;55(4):390-7 - PubMed
  36. J Clin Psychiatry. 2015 May;76(5):575-82 - PubMed
  37. CNS Spectr. 2014 Apr;19(2):121-33 - PubMed
  38. BMC Psychiatry. 2012 May 30;12:52 - PubMed
  39. Basic Clin Pharmacol Toxicol. 2006 Mar;98(3):304-10 - PubMed
  40. Am J Geriatr Psychiatry. 2010 Feb;18(2):128-35 - PubMed
  41. J Affect Disord. 2014 Feb;155:255-60 - PubMed
  42. Am J Geriatr Psychiatry. 2011 Feb;19(2):132-41 - PubMed
  43. J Am Coll Cardiol. 2012 Oct 2;60(14):1207-16 - PubMed
  44. Am J Med. 2006 Jul;119(7):567-73 - PubMed
  45. BMC Psychiatry. 2015 Nov 12;15:277 - PubMed
  46. Am J Psychiatry. 2002 Nov;159(11):1929-32 - PubMed
  47. J Neurosci. 2000 Jun 1;20(11):3993-4001 - PubMed
  48. Am J Geriatr Psychiatry. 2003 Jan-Feb;11(1):46-52 - PubMed
  49. Am J Geriatr Psychiatry. 2011 Feb;19(2):104-14 - PubMed
  50. Psychol Med. 2007 Dec;37(12):1763-73 - PubMed
  51. Diabet Med. 2006 Nov;23(11):1165-73 - PubMed
  52. J Psychopharmacol. 2010 Dec;24(12):1785-92 - PubMed
  53. Clin Pharmacol Ther. 2013 Jun;93(6):493-501 - PubMed
  54. Cerebrovasc Dis. 2014;38(4):284-9 - PubMed
  55. Eur J Pharmacol. 2007 Jan 19;555(1):43-7 - PubMed
  56. Neuropharmacology. 2013 Oct;73:147-59 - PubMed
  57. JAMA Intern Med. 2013 Jun 24;173(12):1150-1 - PubMed
  58. Am J Geriatr Psychiatry. 2010 Nov;18(11):988-98 - PubMed
  59. Lancet. 2007 Sep 8;370(9590):851-8 - PubMed
  60. J ECT. 2012 Mar;28(1):34-8 - PubMed
  61. J Clin Psychopharmacol. 2006 Aug;26(4):379-84 - PubMed
  62. Int Clin Psychopharmacol. 2012 Jul;27(4):215-23 - PubMed
  63. JAMA. 2008 Nov 26;300(20):2379-88 - PubMed
  64. Nihon Rinsho. 2001 Aug;59(8):1574-7 - PubMed
  65. Clin Interv Aging. 2014 Mar 10;9:411-8 - PubMed
  66. J Psychiatry Neurosci. 2015 May;40(3):174-86 - PubMed
  67. J Neurol Sci. 2012 Nov 15;322(1-2):20-4 - PubMed
  68. Int J Clin Exp Med. 2014 Dec 15;7(12):4967-74 - PubMed
  69. Curr Med Res Opin. 2013 Mar;29(3):217-26 - PubMed

Publication Types